TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel
May 6, 2021 2:00 PM EDTStifel analyst Annabel Samimy lowered the price target on TherapeuticsMD (NASDAQ: TXMD) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst commented, "While investor worry remained at a peak, TXMD posted sales of $19.9mn/Cons $19,8mn, with FDA-product sales of $18.3mn coming... More
